Clear Path's January issue pins DynamX's clinical story to specific numbers: 0.3% versus 1.7% TLF in the 6-to-12-month landmark window, 2,400 enrolled patients, a device that "uncages" after six months. Every one of those claims maps to a discrete, queryable field in ClinicalTrials.gov. Enrollment count. Primary completion date. Endpoint definition. Trial status.
These fields can change without a press release, a conference talk, or a trade publication noticing. The registry's last posted update for INFINITY-SWEDEHEART is October 16, 2024. Nothing has invalidated Clear Path's claims yet. But the validation surface is sitting in structured data that Anchor could poll programmatically, and it is a simpler monitoring problem than parsing Okta's newsroom. An API field changing from ACTIVE_NOT_RECRUITING to COMPLETED is unambiguous. A primary completion date shifting forward requires no interpretation at all. The claim-lifecycle mechanism applies here with better infrastructure underneath it.
Registry fields that validate Clear Path claims
- Trial status:
ACTIVE_NOT_RECRUITING— change toCOMPLETEDorTERMINATEDdirectly affects trajectory claims - Primary completion: September 5, 2024 (actual) — already passed; study completion estimated July 2028
- Primary endpoint: TLF at 1 year (cardiovascular death, target-vessel MI, ischemia-driven TLR) — wording change would misalign Clear Path's framing
- Enrollment: 2,400 estimated; ACC reports 2,399 randomized
- FDA PMA database: No U.S. approval exists; Elixir confirms investigational-only status
- Post-market registry: NCT06074549, 5,000 patients, recruiting — a second validation surface